Novartis meningitis B vaccine Bexsero OK'd in US

The FDA on 23 January cleared the way for Novartis to market its much-anticipated meningitis B vaccine Bexsero, which is approved for use in Americans 10-25 years.

The FDA on 23 January cleared the way for Novartis to market its much-anticipated meningitis B vaccine Bexsero, which is approved for use in Americans 10-25 years.

Bexsero is intended to be an active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category